bitFlyer launches ‘Instant Buy’ to make buying cryptocurrency more accessible
5.12.2019 10:00:00 EET | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of Instant Buy on its Buy/Sell exchange platform in Europe. The feature, available on desktop and smartphone, allows users to buy cryptocurrency directly from bitFlyer, using credit card, debit card or local instant transfer methods such as Sofort, iDeal and GiroPay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005083/en/
Instant Buy is now available with bitFlyer Buy/Sell (Photo: Business Wire)
Instant Buy is built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as beginners looking for an all-in-one solution for purchasing, storing and securing their cryptocurrency investments.
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “Instant Buy is the latest upgrade to bitFlyer’s Buy/Sell platform, as part of our goal to create a simpler, faster and transparent experience when it comes to buying virtual currencies. By making it similar to that of a traditional e-commerce experience, we are helping bringing cryptocurrency to a mainstream audience, while also giving experienced users a faster and simpler way to get their currency.”
This new feature, following bitFlyer’s recent app launch, is the latest development in a major growth strategy by the European side of the business in line with its vision to break down barriers to entry that many face while investing in cryptocurrency. Whilst the bitFlyer app has made it even easier for users to buy and sell from their smartphones, Instant Buy makes it more convenient for users to buy coins using their preferred payment method.
Other key features of Instant Buy include:
- Built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as new adopters looking for an all-in-one solution to purchase, store and secure their investments
- Allows users to purchase cryptocurrencies (including the less mainstream altcoins such as Lisk, Monacoin and Ethereum Classic) directly from the bitFlyer platform at a predefined price, making the purchase experience significantly more straightforward
- Any fees related to payment processing are clearly displayed. bitFlyer does not charge additional fees on top of those that may be charged by payment service providers
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell virtual currencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005083/en/
Contact information
Lauren Armour
Tyto PR
+44(0)7826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom